Australian Ethical Investment was hit in 2022, but cushioned the blow

Nick Sundich Nick Sundich, December 15, 2022

Australian Ethical Investment (ASX: AEF) just issued earnings guidance for the half year ending 31 December 2022. As a fund manager, particularly one with exposure to the tech sector, it was hit by the dour market conditions. But it was able to soften the blow and still anticipates an underlying profit.

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

 

Australian Ethical saved from a FUM decline

In 1HY22 (the 6 months to 31  December 2021), Australian Ethical made an underlying (and net) profit of $5.4m and has $6.9bn in Funds Under Management (up 38%).

This morning it told shareholders it anticipated a similar result this time around – a $4.5m-$5m underlying profit. And FUM actually rose to $8.6bn.

The catalyst was the acquisition of Christian Super and its members into the Australian Ethical platform, contributing $1.9bn. It had a wafer-thin net inflow of $0.12bn, but would have seen a decline in FUM to $6.2bn if not for this deal. 

 

Needs to perform in H2

In absence of another M&A deal, Australian Ethical will need improved market conditions to achieve FUM growth. Whether or not it will be achieved is anyone’s guess.

Of course, this is not to say the company is at risk of collapse. It has been around since 1986 and has substantially grown in recent years, even with the Tech Wreck.

In mid-2019, it had just $3.4bn in FUM, barely over a third of what it has now. And as of 30 November 2022, it has over 100,000 super members and over 13,000 managed fund investors. 

 

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

No credit card needed and the trial expires automatically.

 

 

 

Blog Categories

Get Our Top 5 ASX Stocks for FY25

Recent Posts

Orthocell

Orthocell (ASX:OCC): All systems go for a US market roll out of its flagship Remplir nerve repair product

Orthocell (ASX:OCC) is the latest ASX biotech to obtain FDA approval. Its nerve repair product Remplir was already approved in…

how tariffs impact the stock market

Here’s how tariffs impact the stock market and its investors

Many would be wondering how tariffs impact the stock market and its investors. On ‘Liberation Day‘, the returned President Trump…

oldest companies on the ASX

What are the oldest companies on the ASX? Here are 5 of them and the secrets to their success!

In this article, we look at 5 of the oldest companies on the ASX. Now, we are not claiming these…